Who is sponsoring FUTURE12?

FUTURE12 is sponsored by Qun Zhao.

What condition does FUTURE12 study?

FUTURE12 studies Gastric Adenocarcinoma.

What drugs are being tested in FUTURE12?

Interventions: Multimodal AI-driven predictive model.

What is the status of FUTURE12?

FUTURE12 is currently COMPLETED.

Last reviewed 2024-11-15 · How we verify

Multimodal Model Predicts Recurrence (FUTURE12)

NCT06690268 COMPLETED

This study focuses on developing an advanced model that combines clinical information, imaging, and pathology data to predict the likelihood of cancer returning after surgery in patients with locally advanced gastric cancer. By using artificial intelligence (AI), this model analyzes various data sources to create a more accurate prediction of recurrence risk, which can help doctors, patients, and families better understand the chances of recurrence. This AI-driven approach allows healthcare providers to make more informed decisions about personalized follow-up care and potential additional treatments to improve patient outcomes.

Details

Lead sponsor	Qun Zhao
Status	COMPLETED
Enrolment	93
Start date	Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Gastric Adenocarcinoma

Interventions

Multimodal AI-driven predictive model

Countries

China